
## Marta Roman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3234363/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Synthetic Vulnerabilities in the KRAS Pathway. Cancers, 2022, 14, 2837.	3.7	3
2	ld1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of KRAS-mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8+ T Cells. Cancers, 2020, 12, 3169.	3.7	10
3	The Mir181ab1 cluster promotes KRAS-driven oncogenesis and progression in lung and pancreas. Journal of Clinical Investigation, 2020, 130, 1879-1895.	8.2	29
4	Inhibitor of Differentiation-1 Sustains Mutant <i>KRAS</i> -Driven Progression, Maintenance, and Metastasis of Lung Adenocarcinoma via Regulation of a FOSL1 Network. Cancer Research, 2019, 79, 625-638.	0.9	19
5	KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target. Molecular Cancer, 2018, 17, 33.	19.2	237
6	Pazopanib-induced asymptomatic radiological acute pancreatitis: A case report. Molecular and Clinical Oncology, 2017, 6, 651-654.	1.0	3
7	The inhibitor of differentiation-1 (Id1) enables lung cancer liver colonization through activation of an EMT program in tumor cells and establishment of the pre-metastatic niche. Cancer Letters, 2017, 402, 43-51.	7.2	36
8	Endocrine Disruptors: Time to Act. Current Environmental Health Reports, 2014, 1, 325-332.	6.7	13